Arbet-Engels Christophe
SEC insider (Form 3/4/5 filer). CIK 0001802615. Chief Medical Officer at Altimmune, Inc. (ALT) and 1 other issuer. 7 reported Form 4/5 transactions since Sep 2024; latest on Oct 1, 2026. Located in GAITHERSBURG, MD.
Companies Arbet-Engels Christophe has filed insider reports for
- Altimmune, Inc. (ALT): Officer, Chief Medical Officer
- X4 Pharmaceuticals, Inc (XFOR): Officer, Chief Medical Officer
Arbet-Engels Christophe
CIK: 0001802615
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Oct 1, 2026ALT
Altimmune, Inc.
Tax PaymentDirect12.7K shares at avg. $2.76$35K - Oct 1, 2026ALT
Altimmune, Inc.
ExerciseDirect37.5K shares- - Oct 1, 2025ALT
Altimmune, Inc.
AwardDirectRestricted Stock Units
150K shares- - Oct 1, 2025ALT
Altimmune, Inc.
AwardDirectStock Options (option to buy)
450K shares- - Feb 12, 2025XFOR
X4 Pharmaceuticals, Inc
AwardDirect850K shares- - Jan 24, 2025XFOR
X4 Pharmaceuticals, Inc
SaleDirect11.6K shares at avg. $0.45$5K - Jan 23, 2025XFOR
X4 Pharmaceuticals, Inc
AwardDirect25.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  ALT Altimmune, Inc. | Tax Payment | 12,679 | $2.76 | $34,994 | Direct |
| Oct 1, 2026 | ALT Altimmune, Inc. | Exercise | 37,500 | - | $0 | Direct |
| Oct 1, 2025 | ALT Altimmune, Inc. | Award Restricted Stock Units | 150,000 | - | - | Direct |
| Oct 1, 2025 | ALT Altimmune, Inc. | Award Stock Options (option to buy) | 450,000 | - | - | Direct |
| Feb 12, 2025 |  XFOR X4 Pharmaceuticals, Inc | Award | 850,000 | - | - | Direct |
| Jan 24, 2025 | XFOR X4 Pharmaceuticals, Inc | Sale | 11,624 | $0.45 | $5,284 | Direct |
| Jan 23, 2025 | XFOR X4 Pharmaceuticals, Inc | Award | 25,831 | - | $0 | Direct |
1-7 of 7 transactions